Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials

Journal of Stroke and Cerebrovascular Diseases

Volumn 25, Issue 8, 2016, Pages 1984-1996

  Secades, Julio J ^a   Alvarez Sabín, José ^b   Castillo, José ^c   Díez Tejedor, Exuperio ^d   Martínez Vila, Eduardo ^e   Ríos, José ^f   Oudovenko, Natalia ^a  

^a Ferrer Group   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c University Hospital of Santiago de Compostela   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Acute ischemic stroke; CDP choline; citicoline; meta analysis; neuroprotection; pharmacological treatment; systematic review; therapy

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; CITICOLINE; CORTICOSTEROID; CORTICOTROPIN; HYPERTONIC SOLUTION; VASODILATOR AGENT; VITAMIN; NOOTROPIC AGENT;

ARTICLE; BRAIN ISCHEMIA; CLINICAL OUTCOME; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THERAPEUTIC INDEX; COMPLICATION; DOUBLE BLIND PROCEDURE; FEMALE; MALE; PROCEDURES; STROKE;

BRAIN ISCHEMIA; CYTIDINE DIPHOSPHATE CHOLINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84973652548     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2016.04.010     Document Type: Article

References (110)

1. 1 Wang, H., Dwyer-Lindgren, L., Lofgren, K.T., et al. Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2071–2094, 10.1016/S0140-6736(12)61719-X.
2. 2 Lozano, R., Naghavi, M., Foreman, K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128, 10.1016/S0140-6736(12)61728-0.
3. 3 Vos, T., Flaxman, A.D., Naghavi, M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2163–2196, 10.1016/S0140-6736(12)61729-2.
4. 4 Murray, C.J., Vos, T., Lozano, R., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2197–2223, 10.1016/S0140-6736(12)61689-4.
5. 5 Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333 (1995), 1581–1587.
6. 6 Jauch, E.C., Saver, J.L., Adams, H.P. Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44 (2013), 870–947, 10.1161/STR.0b013e318284056a.
7. 7 European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee, Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25 (2008), 457–507, 10.1159/000131083.
8. 8 ESO News: Update Guidelines January 2009, Specific treatment: thrombolysis. Cerebrovasc Dis 27 (2009), 619–620.
9. 9 Shinohara, Y., Yanagihara, T., Abe, K., et al. II. Cerebral infarction/transient ischemic attack (TIA). J Stroke Cerebrovasc Dis 20:Suppl 1 (2011), S31–S73, 10.1016/j.jstrokecerebrovasdis.2011.05.004.
10. 10 Fuentes, B., Díez-Tejedor, E., Stroke units: many questions, some answers. Int J Stroke 4 (2009), 28–37, 10.1111/j.1747-4949.2009.00244.x.
11. 11 Chen, Z.M., Sandercock, P., Pan, H.C., et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups. Stroke 31 (2000), 1240–1249.
12. 12 Vahedi, K., Hofmeijer, J., Juettler, E., et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 6 (2007), 215–222.
13. 13 Berglund, A., Svensson, L., Sjöstrand, C., et al. Higher prehospital priority level of stroke improves thrombolysis frequency and time to stroke unit: the Hyper Acute STroke Alarm (HASTA) study. Stroke 43 (2012), 2666–2670.
14. 14 Kleindorfer, D., de Los Rios La Rosa, F., Khatri, P., et al. Temporal trends in acute stroke management. Stroke 44 (2013), S129–S131, 10.1161/STROKEAHA.113.001457.
15. 15 Roth, J.M., Recombinant tissue plasminogen activator for the treatment of acute ischemic stroke. Proc (Bayl Univ Med Cent) 24 (2011), 257–259.
16. 16 Ali, M., Atula, S., Bath, P.M., et al. Stroke outcome in clinical trial patients deriving from different countries. Stroke 40 (2009), 35–40, 10.1161/STROKEAHA.108.518035.
17. 17 Gray, L.J., Sprigg, N., Bath, P.M., et al. Significant variation in mortality and functional outcome after acute ischaemic stroke between Western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST). J Neurol Neurosurg Psychiatry 77 (2006), 327–333.
18. 18 Heidrich, J., Heuschmann, P.U., Kolominsky-Rabas, P., et al. Variations in the use of diagnostic procedures after acute stroke in Europe: results from the BIOMED II study of stroke care. Eur J Neurol 14 (2007), 255–261.
19. 19 Masjuan, J., Alvarez-Sabín, J., Arenillas, J., et al. [Stroke health care plan (ICTUS II. 2010)]. Neurologia 26 (2011), 383–396, 10.1016/j.nrl.2010.05.008.
20. 20 Ribo, M., Molina, C.A., Pedragosa, A., et al. Geographic differences in acute stroke care in Catalunya: impact of a regional interhospital network. Cerebrovasc Dis 26 (2008), 284–288, 10.1159/000147457.
21. 21 Secades, J.J., Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol 52:Suppl 2 (2011), s1–s62.
22. 22 Gutiérrez-Fernández, M., Rodríguez-Frutos, B., Fuentes, B., et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int 60 (2012), 310–317, 10.1016/j.neuint.2011.12.015.
23. 23 Alvarez-Sabin, J., Roman, G.C., The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci 3 (2013), 1395–1414, 10.3390/brainsci3031395.
24. 24 Citicoline Periodic Safety Updated Report (Jan2011-Dec2011).
25. 25 Saver, J.L., Wilterdink, J., Choline precursors in acute and subacute human stroke: a meta-analysis. Stroke, 33, 2002, 353 [27th International Stroke Conference, San Antonio TX, Feb 2002].
26. 26 Dávalos, A., Castillo, J., Alvarez-Sabín, J., et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 33 (2002), 2850–2857.
27. 27 Lee, M., Towfighi, A., Saver, J.L., Choline precursors in acute and subacute ischemic and hemorrhagic stroke: an updated meta-analysis of randomized controlled trials. Stroke, 41, 2010, e263.
28. 28 Dávalos, A., Alvarez-Sabín, J., Castillo, J., et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 380 (2012), 349–357, 10.1016/S0140-6736(12)60813-7.
29. 29 Lee, M., Towfighi, A., Saver, J.L., Choline precursors for acute and subacute ischemic and hemorrhagic stroke. Cochrane Database Syst Rev(3), 2010, 10.1002/14651858.CD008401 Art. No.: CD008401.
30. 30 Higgins, J.P.T., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
31. 31 Higgins, J.P.T., Green, S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; Available at: http://handbook.cochrane.org/, 2011 Accessed February 26, 2015.
32. 32 Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6, 2009, e1000100, 10.1371/journal.pmed.1000100.
33. 33 De Gregorio, G., Armeli, G., Restivo, S., et al. Valutazione reografica degli effetti angio-emodinamici cerebrali della citidin-difosfocolina nelle sindromi ictali arterioesclerotiche [Rheographic evaluation of the cerebral angio-hemodynamic effects of cytidine diphosphate choline in arteriosclerotic ictal syndromes]. Boll Soc Ital Cardiol 22 (1977), 341–345.
34. 34 Colonna, J.P., Poletto, B., Étude multicentrique de la CDP-choline en Neurologie hospitalière. La Vie Médicale 28-29 (1980), 2317–2318.
35. 35 Schott, B., Joyeux, O., Valutazione dell'impiego della citicolina nella terapia di accidenti ischemici cerebrali. Giorn Ital Ricerche Clin Terap 3 (1982), 56–60.
36. 36 Bellagamba, G., Gentili, G., Caratelli, L., et al. Modificazioni delle plache ateromasiche carotidee e delle condizioni di flusso in pazienti affetti da patologia cerebrovascolare dopo trattamento con CDP-colina [Changes in the carotid atheromatous plaques and in flow conditions in patients with cerebrovascular pathology after treatment with CDP choline. Clinico-instrumental study]. Minerva Cardioangiol 32 (1984), 483–488.
37. 37 Centrone, G., Ragno, G., Calicchio, G., Uso della citicolina ad alti dosaggi nelle affezioni acute cerebro-vascolari [Use of citicoline in high dosages in acute cerebrovascular disease]. Minerva Med 77 (1986), 371–373.
38. 38 Iovine, C., Ricci, A., Neri, G., et al. [Remarks on cyticholine in subjects affected by stroke's outcome and psycho-organic syndrome]. Rass Inter Clin Terap 66 (1986), 1449–1453.
39. 39 Lebedeva, N.V., Lunev, D.K., Shvedkov, V.V., et al. [Recognan therapy of motor disturbances in patients with stroke]. Klin Med (Mosk) 69 (1991), 83–84.
40. 40 Di Mascio, R., Marchioli, R., Vitullo, F., et al. La gestione ospedaliera del paziente cerebrovascolare acuto. Risultati di uno studio condotto nella Regione Abruzzo. Recenti Prog Med 87 (1996), 523–529.
41. 41 Bruhwyler, J., Van Dorpe, J., Geczy, J., Multicentric open-label study of the efficacy and tolerability of citicoline in the treatment of acute cerebral infarction. Curr Ther Res 58 (1997), 309–316.
42. 42 Liu, R.H., Liu, H.L., Clinical investigation on curative effect of dengzhanhua plus citicoline for acute cerebral infarction. Clin Med (Northfield Il) 19 (1999), 36–37.
43. 43 Yu, W., Shen, F., Ma, Z., [Observation of therapeutic effect of Salviae miltiorrhiza and cytosine diphosphate-choline injection on patients with hypertensive cerebral hemorrhage]. Zhongguo Zhong Xi Yi Jie He Za Zhi 20 (2000), 94–96.
44. 44 Shu, G.C., Zhou, W.H., Li, Y.M., Approach the timing and efficacy of citocoline in the treatment of apoplexy. Shanghai Med Pharm J 21 (2000), 33–34.
45. 45 Fridman, E.A., Ottaviano, F., Fiol, M., et al. Neuroproteccion en el ICTUS isquemico agudo. Factibilidad de un protocolo terapeutico [Neuroprotection in acute ischemic stroke. Practicability of guidelines for treatment]. Rev Neurol 32 (2001), 818–821.
46. 46 Yusuf, M., Sadick, A., Efficacy of citicoline in ischemic stroke as a supportive therapy. Pak J Med Sci 17 (2001), 106–111.
47. 47 Shi, F., Zhou, J., Meng, D., [Curative effect of soybean lecithin on cerebral infarction]. Zhonghua Yi Xue Za Zhi 81 (2001), 1301–1303.
48. 48 Zhou, X.G., Chen, S.S., Xiang, X.Z., The clinical observation of magnesium sulfate injection in the treatment of acute stroke. J Chin Gen Med 2 (2001), 18–19.
49. 49 Zhang, L.D., Liu, C.Y., Gu, Y.X., et al. A study of relationship between therapeutic efficacy and therapeutic duration of cranial nerve Growthine (CNG) on patients with intracerebral hemorrhage acute cerebral infarction. J Practic New Med 3 (2001), 677–678.
50. 50 Liu, H.R., Observation of clinical curative effect on acute stage of mild cerebral infarction used cytidine diphosphate choline (CDPC). Hainan Med J 12 (2001), 2–3.
51. 51 Zheng, Y.-P., He, M.-L., A prospect, random, single blind and control study on recovered effect of sermior treatment on motor function of patients with acute cerebral infarction. Chin J Clin Rehabil 6 (2002), 2328–2329.
52. 52 Zhang, G.Z., Dong, S.Q., Dou, W., et al. Effect observation of nerve functional rehabilitation after treatment with cytridini triphophatis on acute ischemia cerebral vascular disease. Chin J Clin Rehabil, 6, 2002, 3292.
53. 53 Li, J.Y., Peng, Y.Z., Yang, F., [Clinical observation on effect of tongnao huoluo acupuncture therapy in treating acute cerebral infarction at ultra-early or acute stage]. Zhongguo Zhong Xi Yi Jie He Za Zhi 23 (2003), 736–739.
54. 54 Garcia, A., Diaz, F., Gil-Nuñez, A.C., et al. Tolerability and efficacy of the combination of piracetam and citicoline in acute ischemic stroke. A randomized comparative open study. 5th World Stroke Congress, Vancouver, Canada, 2004.
55. 55 Zhong, S.Q., Sun, L.J., Yan, Y.Z., et al. Effect of Xuesaitong soft capsule on hemorrheology and in auxiliarily treating patients with acute cerebral infarction. Chin J Integr Med 11 (2005), 128–131.
56. 56 Jiang, H., Wang, M., Guo, J., et al. The midnight-noon ebb-flow point selection for 30 cases of acute ischemic cerebrovascular diseases. J Tradit Chin Med 28 (2008), 193–197.
57. 57 Cho, H.J., Kim, Y.J., Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4191 cases. Methods Find Exp Clin Pharmacol 31 (2009), 171–176, 10.1358/mf.2009.31.3.1364241.
58. 58 Mousavi, S., Zare, M., Khorvash, F., et al. Evaluation of citicholine effect in acute phase of supratentorial hemorrhage: a randomized placebo-controlled clinical trial. J Cell Tiss Res 9 (2009), 1773–1776.
59. 59 Mousavi, S.A., Zare, M., Khorvash, F., et al. Evaluation of citicholine effect in acute phase of stroke: a randomized clinical trial. J Cell Tiss Res 9 (2009), 1785–1788.
60. 60 Panteleienko, L., Sokolova, L., Patients treated with citicoline in acute phase of ischemic stroke report better quality of life. Eur J Neurol, 16(3 Suppl), 2009, 412.
61. 61 Leon-Jimenez, C., Chiquete, E., Cantu, C., et al. Citicoline for acute ischemic stroke in Mexican hospitals: a retrospective postmarketing analysis. Methods Find Exp Clin Pharmacol 32 (2010), 325–330, 10.1358/mf.2010.32.5.1465004.
62. 62 Shamalov, N.A., Stakhovskaia, L.V., Shetova, I.M., et al. [Efficacy and safety of the combined therapy with citicholine and actovegin in the acute period of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova 110:9 Pt 2 (2010), 13–17.
63. 63 Makrotova, T.A., Chefranova, Z., Titiva, L., Combination of thrombolytic therapy with citicoline in treatment acute ischaemic stroke. 20th European Stroke Conference, Hamburg, Germany, 2011.
64. 64 Sobrino, T., Rodríguez-González, R., Blanco, M., et al. CDP-choline treatment increases circulating endothelial progenitor cells in acute ischemic stroke. Neurol Res 33 (2011), 572–577, 10.1179/016164110X12807570510176.
65. 65 Ershov, V.I., [Comparative aspects of using neuroprotectors in the management of patients with ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova 111:8 Pt 2 (2011), 41–44.
66. 66 Martynov, M.I., Boiko, A.N., Kamchatnov, P.R., et al. [Neuroprotective treatment with citicoline (Ceraxon) in patients with ischemic stroke.]. Zh Nevrol Psikhiatr Im S S Korsakova 112:3 Stroke (2012), 21–26.
67. 67 Piradov, M.A., Sergeev, D.V., Krotenkova, M.V., Citicoline (Ceraxon) in acute stroke: assessment of clinical efficacy and effects on cerebral perfusion. Ann Clin Exp Neurol 6 (2012), 31–36.
68. 68 Mitta, M., Goel, D., Bansal, K.K., et al. Edaravone—citicoline comparative study in acute ischemic stroke (ECCS-AIS). J Assoc Physicians India 60 (2012), 36–38.
69. 69 Vaizova, O.E., Zautner, N.A., Alifirova, V.M., et al. [Influence of neuroprotectors with choline-positive action on the level of brain-injury markers during acute ischemic stroke]. Eksp Klin Farmakol 75 (2012), 7–9.
70. 70 Tazaki, Y., Otomo, E., Kutsuzawa, N., et al. Clinical effect of CDP-choline (Nicholin) on disturbance of consciousness in acute stage of stroke (1st report): pre-test by the multicenter double-blind placebo-controlled method. Ther Res 3 (1985), 883–903.
71. 71 Tazaki, Y., Oyomo, E., Kutsuzawa, T., et al. Clinical effect of CDP-choline (Nicholin) on disturbance of consciousness at the acute stage of stroke. Multicenter, double-blind, placebo controlled study. Igaku No Ayumi 136 (1986), 719–817.
72. 72 Pardo Cid, P., Andres, A.I., Fernandez, N., et al. Stroke CDP-choline trial: difficulties of patient selection for randomised intervention trials. Z Gerontol Geriatr, 32(2 Suppl), 1999 II-263.
73. 73 Dereux, J.F., Gallois, P., Resultats comparatifs ACTH/citicoline dans la phase initiale des infarctus cerebraux. Gaz Med 94 (1987), 82–85.
74. 74 Ortolani, O., Caggiano, M., Mannelli, R., et al. Protection from ischemia-reperfusion damage in patients with stroke: the role of rutin and GSH. Transplant Proc 27 (1995), 2877–2878.
75. 75 Zhang, L., Li, H.Y., Li, Y.Z., Citicoline capsules vs piracetam tablets in treatment of cerebral infarction. Chin J New Drugs Clin Rem 21 (2002), 202–204.
76. 76 Zhou, M.E., He, L., Kong, S.Y., et al. Efficacy and safety of sodium citicoline tablets in the treatment of acute cerebral hemorrhage: a randomized controlled trial. Chin J Evid Based Med 5 (2005), 818–821.
77. 77 Djoenaidi, W., Hendro, S., Adril, A.H., et al. A double-blind controlled trial of cytidine-diphosphate-choline (CDP-choline) on thrombotic stroke patients. 12th World Congress of Neurology, Kyoto (Japan); September, 1981.
78. 78 Martínez, S.M., Porras, M.A., Alvarado, M.A., Papel del 5′-citidin-difosfato de colina en la isquemia cerebral del anciano: Estudio a doble ciego en pacientes con coma debido a accidente vascular cerebral agudo de tipo oclusivo. Congreso por el Año Jubilar de la Sociedad Peruana de Psiquiatría, Neurología y Neurocirugía, 1988.
79. 79 Guillén, F., Buendia, C., Herrera, J., CDP-choline in the treatment of acute ischaemic stroke. 5th Meeting of ENS, Munich, 1995.
80. 80 Secades, J.J., Alvarez-Sabín, J., Rubio, F., et al. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis 21 (2006), 380–385.
81. 81 Chua, R., Role of intravenous citicoline for supratentorial hemorrhage. Cerebrovasc Dis, 23(4 Suppl), 2007, 73.
82. 82 Wang, Y.D., Lu, R.Y., Huang, X.X., et al. Human tissue kallikrein promoted activation of the ipsilesional sensorimotor cortex after acute cerebral infarction. Eur Neurol 65 (2011), 208–214, 10.1159/000325735.
83. 83 Bisantis, C., Colosi, P., Fiorentino, F., [Double blind clinical experimentation of CDP-coline on carotid circle by ophthalmodinamometric valuation]. Ann Ottalmol Clin Ocul 108 (1982), 865–872.
84. 84 Kameyama, M., Ohtomo, E., Koshijima, S., et al. Effect of citicoline (CDP-choline) on cerebrovascular diseases. A controlled clinical trial with a double-blind method. Clin Evaluation/Rinsho Hyoka 2 (1974), 429–439.
85. 85 Pardo, P., Andres, A.I., Castro, C., et al. ACVA: dificultades de selección de pacientes en estudios de intervencion randomizados. Rev Esp Geriatr Gerontol, 33(S1), 1998, 57.
86. 86 Boudouresques, A.B., Michel, B., Therapeutic conduct in light of a cerebral vascular accident and the use of CDP-choline. in French; Presented at; International Symposium: Brain Suffering and Precursors of Phospholipids. Paris; January 18, 1980 109-121.
87. 87 Goas, J.Y., Bastard, J., Missoum, A., Results after 90 days of stroke treatment with CDP choline, concerning a double blind trial. in French; Presented at; International Symposium: Brain Suffering and Precursors of Phospholipids. Paris; January 18, 1980, 123–128.
88. 88 Corso, E.A., Arena, M., Ventimiglia, A., et al. La CDPCcolina nelle vasculopatie cerebrali: valutazioni cliniche e di semeiologia strumentale [CDP choline in cerebral vasculopathy: clinical evaluation and instrumental semeiology]. Clin Ter 102 (1982), 379–386.
89. 89 Tazaki, Y., Sakai, F., Otomo, E., et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind controlled study. Stroke 19 (1988), 211–216.
90. 90 Clark, W.M., Warach, S.J., Pettigrew, L.C., et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 49 (1997), 671–678.
91. 91 Clark, W.M., Williams, B.J., Selzer, K.A., et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 30 (1999), 2592–2597.
92. 92 Warach, S., Pettigrew, L.C., Dashe, J.F., et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 48 (2000), 713–722.
93. 93 Clark, W.M., Wechsler, L.R., Sabounjian, L.A., et al. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 57 (2001), 1595–1602.
94. 94 Alviarez, E., Gonzalez, M., Efectividad y tolerabilidad de la Citicolina en el ICTUS Isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo. Archivos Venezolanos de Farmacologia y Terapeutica 26 (2007), 127–130.
95. 95 Juni, P., Witschi, A., Bloch, R., et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282 (1999), 1054–1060.
96. 96 Rothwell, P.M., External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 365 (2005), 82–93.
97. 97 Martinez-Vila, E., Irimia, P., Challenges of neuroprotection and neurorestoration in ischemic stroke treatment. Cerebrovasc Dis 20:2 Suppl (2005), 148–158.
98. 98 Kaplan, B.J., Giesbrecht, G., Shannon, S., et al. Evaluating treatments in health care: the instability of a one-legged stool. BMC Med Res Methodol, 11, 2011, 65, 10.1186/1471-2288-11-65.
99. 99 Kidwell, C.S., Liebeskind, D.S., Starkman, S., et al. Trends in acute ischemic stroke trials through the 20th century. Stroke 32 (2001), 1349–1359.
100. 100 Lopez, G.A., Afshinnik, A., Samuels, O., Care of the stroke patient: routine management to lifesaving treatment options. Neurother 8 (2011), 414–424, 10.1007/s13311-011-0061-1.
101. 101 Moher, D., Jadad, A.R., Nichol, G., et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 16 (1995), 62–73.
102. 102 Bath, P.M., Gray, L.J., Systematic reviews as a tool for planning and interpreting trials. Int J Stroke 4 (2009), 23–27, 10.1111/j.1747-4949.2009.00235.x.
103. 103 Ioannidis, J.P.A., Cappelleri, J.C., Lau, J., Issues in comparisons between meta-analyses and large trials. JAMA 279 (1998), 1089–1093.
104. 104 Thompson, S.G., Higgins, J.P., Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit?. Lancet 365 (2005), 341–346.
105. 105 LeLorier, J., Grégoire, G., Benhaddad, A., et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 337 (1997), 536–542.
106. 106 Finniss, D.G., Kaptchuk, T.J., Miller, F., et al. Biological, clinical, and ethical advances of placebo effects. Lancet 375 (2010), 686–695, 10.1016/S0140-6736(09)61706-2.
107. 107 Feigin, V.L., Lawes, C.M., Bennett, D.A., et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 8 (2009), 355–369, 10.1016/S1474-4422(09)70025-0.
108. 108 Hermann, D.M., Chopp, M., Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol 11 (2012), 369–380, 10.1016/S1474-4422(12)70039-X.
109. 109 Shuaib, A., Lees, K.R., Lyden, P., et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357 (2007), 562–571.
110. 110 Ringelstein, E.B., Thijs, V., Norrving, B., et al. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke Trial. Stroke 44 (2013), 2681–2687, 10.1161/STROKEAHA.113.001531.